Objective-Vascular smooth muscle cell (VSMC) apoptosis occurs at low levels in atherosclerotic plaques and in vessel remodeling; however, the consequences and mediators of these levels are not known. Akt1 protects against VSMC apoptosis largely through inactivating target proteins such as forkhead class O transcription factor 3a (FoxO3a), but Akt1 signaling is reduced and FoxO3a activity is increased in human atherosclerosis. We therefore sought to determine whether inhibition of VSMC apoptosis via Akt1 activation regulates vessel remodeling and atherogenesis and to identify FoxO3a target proteins that mediate VSMC apoptosis. Approach and Results-We generated mice that express an Akt1 protein that can be activated specifically in arterial VSMCs.
V ascular smooth muscle cell (VSMC) apoptosis occurs in physiological vessel remodeling, for example, after flow reduction, [1] [2] [3] in disease states such as atherosclerosis, 4 and after injury. Indeed, supraphysiological VSMC apoptosis after flow reduction promotes negative remodeling, in part by increasing neointimal formation and medial repair, by inducing proliferation, migration, and matrix synthesis of adjacent viable VSMCs. 5 Supraphysiological VSMC apoptosis in atherosclerosis results in multiple features of plaque vulnerability, including a thinner fibrous cap heavily infiltrated with inflammatory cells, an enlarged necrotic core, and reduced collagen content. 6, 7 Although these models are informative, the normal vessel wall shows no detectable VSMC apoptosis; apoptotic rates in remodeling and atherosclerosis are <2%; and the majority of identifiable apoptotic cells in plaques have macrophage markers. 4 Thus, determination of the impact of this low level of VSMC apoptosis during physiological or pathological situations is difficult, and the endogenous regulators of VSMC apoptosis in vivo have not been identified.
Insulin-like growth factor-1 (IGF1) is a potent antiapoptotic cytokine for VSMCs in vitro, mediated predominantly through the serine-threonine kinase Akt1 (oncogene identified in the AKT8 retrovirus). Akt is sufficient and essential for IGF1-mediated VSMC survival in culture during oxidative stress, 8 and IGF1 receptor expression and signaling is reduced in human plaque VSMCs, 9, 10 mediated in part through p53induced repression of IGF1R expression. 10 Akt inhibits apoptosis by phosphorylation of proapoptotic proteins such as Bad, IκB kinase-α, caspase 9, glycogen synthase kinase-3 (GSK3), 11 and forkhead class O transcription factor 3a (FoxO3a). 12, 13 Akt phosphorylation of FoxO proteins results in trafficking out of the nucleus and sequestration by 14.3.3 proteins, promoting proteasomal degradation. 14 We have shown previously that Akt-dependent inhibition of FoxO3a is critical for VSMC survival in vitro, and that both phosphorylated Akt (active) and phosphorylated FoxO3a (inactive) are coexpressed in medial VSMCs underlying human atherosclerotic plaques; in contrast, plaque intimal VSMCs exhibit reduced p-Akt and a concomitant increase in unphosphorylated active FoxO3a. 8 FoxO3a promotes VSMC growth arrest and apoptosis after vascular injury, 15, 16 suggesting that Akt-dependent regulation of FoxO3a activity is important in vivo.
Consistent with Akt1 protecting VSMCs in vivo, wholebody genetic depletion of Akt1 increases atherosclerosis, reduces VSMC migration and survival, and induces features of plaque vulnerability and cardiac dysfunction. 17, 18 However, there are caveats when interpreting these data. First, the mice lacked Akt1 in all cells, such that decreased viability of other cell types (eg, endothelial cells and macrophages) may alter plaque structure. 17 Second, these mice develop in the absence of Akt1, such that compensatory events during development may affect the final phenotype. Third, other effects of Akt1 on VSMCs such as migration and proliferation rather than apoptosis might contribute to changes in plaque structure. 18 Finally, it is important to determine whether the low physiological levels of VSMC death during atherogenesis 4 or remodeling 3, 5 contribute to disease and whether this can only be achieved by preventing VSMC apoptosis.
Using transgenic mice in which the switchable Akt1 allele myristoylated Akt1-estradiol receptor (mAktER) 8 is targeted exclusively to large artery VSMCs, we show that Akt1 expression regulates VSMC apoptosis in vessel remodeling and atherosclerosis and identify the likely transcriptional targets of FoxO3a that mediate VSMC apoptosis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Generation and Characterization of SM22α∆G/C mAktER Mice
To inhibit VSMC apoptosis in vivo, we generated transgenic mice expressing the SM22α∆G/C mAktER transgene. This transgene comprises the minimal smooth muscle protein 22α promoter (−447 to +89 relative to the transcriptional start site) lacking the G/C-rich repressor region (−256 to −249), 19 driving human Akt1 lacking the pleckstrin homology domain, but with an amino terminal myristoylation domain, an internal human influenza hemagglutinin tag, and a modified ligandbinding domain of the estrogen receptor 20 fused to the carboxy terminus. The transgene also contains a polyA site for RNA stability ( Figure I in the online-only Data Supplement). We have previously demonstrated that the downstream signaling from the Akt1ER fusion protein is identical for Akt1 phosphorylation, targets of Akt1 (Akt itself, FoxO3a, GSK3), and their kinetics of induction compared with IGF1, a known stimulus for Akt1 phosphorylation, and that Akt1ER activation does not reduce phosphorylation of endogenous Akt1 8 ; thus, the Akt1ER fusion protein is functionally identical to activation of Akt1. Data are presented from 2 founders (31 and 34), although a third founder (37) gave comparable results. mAktER founders were crossed to C57/Bl6 mice and transgene transmission confirmed by polymerase chain reaction. Transgene RNA and protein expression were determined by reverse transcription-polymerase chain reaction ( Figure 1A ) and immunohistochemistry ( Figure 1B ). Although the Akt antibody used detects both transgenically expressed mAktER and endogenous Akt, only transgenic mice were positive for hemagglutinin ( Figure 1B ). Hemagglutinin-tagged mAktER expression was restricted to VSMCs and not detected in heart, liver, or SMC-rich organs such as bladder ( Figure II in the online-only Data Supplement), consistent with other studies using this promoter, 7 including the G/C-rich deleted variant. 19 mAktER expression did not significantly alter expression of endogenous Akt1, 2, or 3 in VSMCs cultured from these mice ( Figure IIIA in the online-only Data Supplement). To confirm that the mAktER protein can be activated in vivo, we examined expression of phosphorylated and unphosphorylated Akt and its downstream substrates GSK3 and FoxO1/3a at baseline and 24 hours after tamoxifen administration in mAk-tER or control mice. In mAktER mice, p-Akt, p-GSK3, and p-FoxO increased relative to unphosphorylated forms to levels significantly above control littermates ( Figure 1C ; Figure IIIB in the online-only Data Supplement).
Effects of Prolonged Akt Activation in VSMCs
Akt can have pleiotropic effects in VSMCs, including proliferation, survival, and migration 18 ; thus, sustained mAk-tER activation might affect normal vessel structure. We, therefore, administered tamoxifen continuously for 6 weeks to transgenic and control mice and examined vessel morphology. Forty-three percent VSMCs expressed p-Akt in transgenic animals compared with 7% in control mice, indicating that mAktER activation can be maintained by repeated tamoxifen administration ( Figure 
Effect of Akt Activation on VSMC Apoptosis In Vivo
To examine the role of Akt-mediated VSMC survival in vivo, heterozygous mAktER or littermate control mice were administered tamoxifen for 2 weeks and then underwent carotid artery ligation. Medial VSMC apoptosis occurs in this model at 7 to 14 days. 3, 5 Apoptosis was markedly reduced in mAk-tER mice (1.2±1.1% versus 10.7±9.4%; P=0.005; Figure 2A ), indicating that Akt activation potently inhibits VSMC apoptosis after carotid ligation. Mice were examined at 28 days for morphometry, cell proliferation (bromodeoxyuridine [BrdU]), and intimal BrdU-negative cells, a surrogate measure of cell migration in this model. 3, 5 Carotid ligation in C57Bl6 mice normally reduces lumen area (negative remodeling) and can increase intimal and intimal plus medial area and their respective cell counts. 5 Baseline vessel parameters (lumen area, vessel perimeter, medial area, and cellularity) were similar between groups before ligation. Intimal or medial areas, intimal/medial ratios, and cell counts were similar in mAk-tER and control mice at 28 days, although intimal VSMCs in mAktER mice showed increased BrdU-positive and reduced BrdU-negative cells. In contrast, mAktER mice showed a 30% increase in lumen area after ligation, indicating that Akt inhibits negative remodeling seen after flow reduction (Table) .
Effects of Akt Activation in VSMCs on Atherogenesis
We next examined the effects of inhibiting the chronic lowlevel VSMC apoptosis during atherogenesis. Male and female SM22α∆G/C mAktER /+ /apoE −/− and littermate control apoE −/− mice were fat-fed and concurrently administered tamoxifen from 6 to 20 weeks of age. There was no sex difference between groups. BrdU was administered 2 weeks before euthanization. Body weight, serum cholesterol, triglycerides, low-density lipoprotein, and high-density lipoprotein were similar in SM22α∆G/C mAktER /+ /apoE −/− and control apoE −/− animals at all time points tested ( Table I in the online-only  Data Supplement) . Although VSMC apoptosis rates are low in mature mouse and human plaques, 4, 7 Akt activation affected plaque morphology. Absolute fibrous cap areas were similar between transgenic and control mice; however, because plaque size was 39% smaller in SM22α∆G/C mAktER /+ /apoE −/− mice (a trend that did not reach statistical significance; P=0.058), the fibrous cap area/plaque area was significantly increased in SM22α∆G/C mAktER /+ /apoE −/− mice (P=0.004), indicating a relative increase in fibrous cap thickness ( Figure 2B ; Table) . Fibrous cap VSMC cellularity was maintained, indicating preservation of both cell number and VSMC synthetic products. There was a trend to increased collagen content of the whole plaque in SM22α∆G/C mAktER /+ /apoE −/− , but no change in necrotic core percentage ( Figure 2B ; Table) . Although the proportion of macrophages was similar, there was an increase in the percentage of VSMCs in SM22α∆G/C mAktER /+ /apoE −/− mice (Table) . Apoptosis of VSMCs (identified by expression of α-smooth muscle actin) was determined by terminal deoxynucleotidyl transferase dUTP end labeling ( Figure 2C ). Although only a low level was detected in control mice (6 apoptotic VSMCs in 24 plaques), this was completely suppressed in SM22α∆G/C mAktER /+ /apoE −/− mice (no apoptotic VSMCs in 30 plaques). Proliferation rates of VSMCs were very low (<0.1%) and were similar between groups, suggesting that the relatively enlarged fibrous cap of SM22α∆G/C mAktER /+ /apoE −/− mice arose because of Akt-dependent survival rather than increased proliferation.
Mechanisms of Akt-Dependent VSMC Survival
These data confirm that Akt regulates VSMC survival during remodeling and atherogenesis in vivo; we therefore examined the mechanisms of Akt-dependent VSMC survival. Although Akt regulates activity of many downstream proteins, FoxO3a inhibition is essential for VSMC survival in vitro. 8 Moreover, phosphorylated FoxO1/3a expression is reduced in intimal VSMCs of human plaques, 8 implying that FoxO3a promotes VSMC apoptosis in plaques. Although, FoxO3a is a potent inducer of VSMC apoptosis, 15, 16 it has multiple transcriptional targets including genes involved in growth arrest and apoptosis such as p27, bim, puma, gadd45α, and fasL. 21, 22 Nonetheless, FoxO3a targets in VSMCs may be different from other cells and not involved in apoptosis. 8 To identify FoxO3a-regulated genes in VSMCs, we generated VSMCs expressing FoxO3aA3ER; Figure 3A , top panel), a 4-hydroxytamoxifen (HT)-activated FoxO3a variant that is not inhibited by Akt because of mutation of 3 Akt phosphorylation sites (T32A/S253A/S315A). 13 HT-dependent FoxO3aA3ER activation rapidly induced activity of a luciferase reporter containing 3 copies of a FoxO response element (data not shown) and induced apoptosis that was not inhibited by serum or IGF1 ( Figure VII in the online-only Data Supplement; data not shown), confirming that FoxO3aA3ER was refractory to IGF1/Akt signaling.
HT-dependent activation of FoxO3aA3ER VSMCs regulated known FoxO3a targets. For example, HT increased both protein ( Figure 3A ) and RNA ( Figure 3B ) of p21, bim, puma, and gadd45α and reduced cyclin D1, a known repression target, 21 consistent with FoxO3aA3ER retaining both transactivation and transrepression activities of the native protein. HT has partial agonist activity of the endogenous estrogen receptor in VSMCs, and we detected some induction of p21 and gadd45α mRNAs even without FoxO3aA3ER expression (data not shown); however, other FoxO3a targets (eg, bim and puma) were not affected by HT alone ( Figure 3A) . We therefore compared HT-dependent gene regulation in FoxO3aA3ER-expressing cells with similarly treated control cells to subtract any effects of HT alone.
Identification of FoxO3a Targets
Changes in gene expression 4 hours after HT treatment of FoxO3aA3ER compared with control VSMCs were determined by microarray covering 27 342 genes. This yielded 3467 Morphometric data of carotid arteries 28 d after ligation in tamoxifen-treated control or mAktER mice, or characteristics of atherosclerotic plaques of control ApoE −/− or SM22α∆G/C mAktER /+ /ApoE −/− mice fed a high-fat diet and administered 1 mg tamoxifen thrice weekly for 14 wk. Results are mean±SD. Apaf1 indicates apoptotic protease activating factor 1; BrdU, bromodeoxyuridine; mAktER, myristoylated Akt1-estradiol receptor; and VSMC, vascular smooth muscle cell. upregulated and 4412 downregulated genes. Subsequent analysis was refined by selecting potential targets that fulfilled 2 further parameters: (1) >2-fold change and (2) possessing at least 1 predicted FoxO-binding site (A/GTAAAT/CA or C/TTAAAA/ GA) within −5000 to +200 bp of the transcription start site of both rat and human promoters. These criteria indicated 655 upregulated and 677 downregulated genes (https://www. bioc.cam.ac.uk/people/uto/littlewood). The complete data set includes many known FoxO3a targets such as p27 (CDKN1B; +2.85-fold), cyclin D1 (−2.76-fold), bim (bcl2l11; +6.24 fold), bcl6 (+3.41-fold), gadd45α (+4.29-fold), and matrix metalloproteinase 13 (+371-fold) but not puma (which is absent from the chip). Ingenuity Pathway Analysis software identified multiple pathways, including those regulating DNA replication and repair, cancer, cell signaling, cardiovascular system development and disease, and free radical scavenging, including 98 genes involved in apoptosis. One of these, apoptotic protease activating factor 1 (apaf1), has a central role in apoptosis, 23 but has not been identified as a FoxO3a target; its involvement in VSMC death was therefore investigated further.
Apaf1 Is a Bona Fide FoxO3a Target That Regulates FoxO3a-Mediated Apoptosis
HT treatment of FoxO3aA3ER VSMCs increased apaf1 RNA 3.5-fold at 4 hours ( Figure VII in the online-only Data Supplement) and Apaf1 protein from ≈8 hours ( Figure 3C) ; this was not seen in control VSMCs. Consistent with apaf1 being a bona fide transcriptional target of FoxO3a, apaf1 induction did not require new protein synthesis or an increase in other FoxO species 24 during the same time period ( Figure VII in the online-only Data Supplement). FoxO3a and p53 activate many of the same transcriptional targets including apaf1, 25 and FoxO3a can induce p53 accumulation and p53-dependent apoptosis. 26 However, small interfering RNA-mediated reduction of endogenous p53 did not reduce apaf1 RNA after HT treatment ( Figure VIII in the online-only Data Supplement) suggesting that apaf1 induction by FoxO3a does not require p53. No changes were observed in gapdh RNA with or without small interfering RNA and HT.
Bioinformatics analysis of the rat apaf1 promoter revealed that it contains at least 19 putative FoxO3a-binding sites A/G TAAA T/C A, C/T TAAA A/G A, 13 or TTGTTTAC, 27 spanning a region 5000 bp upstream from the transcriptional start site. Within this range, one consensus sequence was conserved between 3 species (human, mouse, and rat; Figure IX in the online-only Data Supplement). Deletion mutants of this consensus site ( Figure IX in the online-only Data Supplement) within a luciferase reporter construct containing −871 to +208 relative to the start of exon 1 of the human apaf1 promoter (a kind gift from Kristian Helin) 25 showed decreased luciferase activity compared with the wild-type promoter ( Figure 4A ), indicating that this is a major site of FoxO3a binding. However, these mutants retained some activity indicating additional potential FoxO3a-binding sites. None of the apaf1 luciferase reporters exhibited any activity in control VSMCs. Immunoprecipitation of chromatin complexes with a FoxO3a antibody demonstrated enrichment of the endogenous apaf1 promoter after HT-dependent activation of FoxO3aA3ER ( Figure 4B ). The Gadd45α promoter sequence, a known FoxO3a target, was also enriched in these assays. No enrichment of either target with a nonspecific rabbit immunoglobulin was observed, indicating that apaf1 is a direct transcriptional target of FoxO3a in VSMCs. We reasoned that increased Apaf1 expression after FoxO3a activation might decrease the threshold at which cells undergo apoptosis. Small interfering RNA-mediated inhibition of Apaf1 ( Figure X in the online-only Data Supplement) reduced (at 16 hours) and delayed the extent of apoptosis after HT-dependent activation of FoxO3aA3ER as demonstrated by time lapse microscopy ( Figure 4C ) and Annexin V/propidium iodide staining (not shown).
Finally, we examined Apaf1 expression in VSMCs in atherosclerotic plaques compared with expression of FoxO3a. Concomitant with reduced IGF1/Akt signaling and increased FoxO3a activity (reduced p-FoxO3a) described previously, Apaf1 was increased in plaque intimal VSMCs of human carotid lesions (American Heart Association grade IV to V) compared with normal aorta. Apaf1 was also reduced in VSMCs of plaques of tamoxifen-treated mAktER /+ /ApoE −/− mice ( Figure 5 ; Table) , suggesting that Akt-dependent repression of FoxO3a and its proapoptotic target apaf1 may be important in atherogenesis. 
Discussion
VSMC apoptosis is observed during development, physiological and pathological remodeling, and in multiple vascular diseases, including atherosclerosis, after angioplasty, aneurysm formation, and transplant arteriopathy. 28 VSMC apoptosis occurs within hours to days of flow changes in remodeling until the final vessel caliber is established. Augmentation of VSMC apoptosis can promote negative remodeling (shrinkage) after flow reduction, in part through changes in neointima and overall vessel size. 5 In atherosclerosis, augmentation of VSMC apoptosis is associated with multiple features of vulnerable plaques. 7, 29 However, endogenous rates of VSMC apoptosis are far lower than seen in these models, and it is unclear whether the low-level VSMC apoptosis that occurs during remodeling or atherogenesis contributes to either pathology, particularly in situations where the VSMCs retain the ability to proliferate. The mechanisms that promote VSMC survival in the vessel wall are also mostly unknown.
We generated mice expressing mAktER specifically in VSMCs of large arteries by expression from the minimal SM22α promoter; additional deletion of the G/C-rich region from this promoter prevents its repression in atherosclerosis. 19 mAktER was expressed exclusively in arterial VSMCs and could be rapidly and continuously activated in vivo by tamoxifen administration, as demonstrated by phosphorylation of Akt, GSK3, and FoxO. Activated mAktER suppressed VSMC apoptosis after carotid ligation and in mature atherosclerotic plaques. Thus, mAktER was both expressed and functionally competent to phosphorylate target genes and suppress endogenous levels of VSMC apoptosis in these models.
Artery structure and cellularity from mAktER mice were similar to control mice both before and after mAktER activation, indicating that Akt activation alone does not promote VSMC proliferation or induce neointima formation. However, Akt activation inhibited VSMC apoptosis and negative remodeling after carotid ligation, indicating that Akt-dependent VSMC survival regulates vessel architecture and final vessel caliber after changes in flow. Atherosclerotic plaques in fat-fed mAktER/ApoE −/− mice showed a significant increase in fibrous cap area relative to plaque size, in part because of a 39% reduction in plaque size. These effects are most likely because of reduced VSMC apoptosis as we found complete suppression of VSMC apoptosis in mAktER mice and no difference in VSMC proliferation, and are consistent with reduced fibrous cap area and increased atherosclerosis when VSMC apoptosis is induced ectopically. 29 Our results indicate that even low endogenous levels of VSMC apoptosis promote relative fibrous cap thinning and could increase atherogenesis. This may seem paradoxical when VSMCs are capable of proliferation and thus replacing dead cells. However, VSMCs in fibrous caps of advanced plaques demonstrate extensive DNA damage and markers of senescence 30 ; even rare VSMC apoptosis could cause extensive cell loss over time if adjacent VSMCs are incapable of proliferating, making the combination of VSMC apoptosis and senescence a potent mechanism of fibrous cap thinning. The effects of VSMC apoptosis may also be amplified by the failure of phagocytosis seen in atherosclerosis. 31 Secondary necrosis releases cytokines such as interleukin-1, monocyte chemoattractant protein-1, and interleukin-6, 32 and VSMC apoptosis induces marked inflammation in the fibrous cap, 7 a feature of human vulnerable plaques. The endogenous protective signals that suppress VSMC apoptosis in vivo are mostly unknown. We have shown that Akt-dependent inhibition of FoxO3a mediates IGF1dependent suppression of VSMC apoptosis. 8 Similarly, Akt2 protects against aortic aneurysm formation by preventing FoxO1 associating with the matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 promoters, 33 and also protects against atherosclerosis in low-density lipoprotein receptor-null mice. 34 Our study demonstrates that Aktdependent phosphorylation of FoxO3a occurs in vivo and identifies several novel FoxO3a transcriptional targets in VSMCs. In particular, Apaf1 is a major component of the apoptotic pathway, required for caspase 9 activation after cytochrome c release from mitochondria. Apaf1 is transcriptionally induced by apoptotic effectors such as p53, but is not a recognized transcriptional target of FoxO3a. We show that apaf1 is a bona fide FoxO3a transcriptional target with FoxO3a consensus sequences in its promoter. FoxO3a binds and activates the apaf1 promoter, and inhibition of FoxO3adependent apaf1 expression delays VSMC apoptosis in vitro. We have previously shown that VSMCs in human plaques have reduced IGF1 signaling, increased FoxO3a activity, and increased apoptosis compared with medial VSMCs or in nondiseased vessel VSMCs 8 ; here we show that VSMCs in human lesions have increased Apaf1 expression, which could be suppressed in mice by Akt activation. Although not a proof, this colocalization strongly suggests that the Akt-FoxO3a-Apaf1 apoptotic pathway is important in human atherosclerosis.
Although we have previously shown that FoxO3a is the major antiapoptotic target of Akt1 in VSMCs, 8 it is likely that other Akt protective signaling pathways may also contribute. For example, phosphorylation of the proapoptotic protein Bad by Akt inhibits its activity, and Akt-dependent inhibition of GSK3 activity prevents phosphorylation and subsequent proteasomal targeting of the antiapoptotic myeloid cell leukemia-1 protein. 8, 35 Akt can also positively regulate other proteins, such as 70-kDa S6 kinase, the antiapoptotic nuclear factor-κB, 36, 37 and murine double minute-2. 38 Murine double minute-2 is an E3 ubiquitin ligase responsible for enhanced degradation of p53, whose transcriptional targets include proapoptotic proteins such as Puma and Noxa. Thus, Akt-mediated murine double minute-2 activation inhibits p53-dependent apoptosis.
In conclusion, we show that VSMC apoptosis regulates vessel remodeling after changes in flow. In addition, suppression of the chronic low-level endogenous VSMC apoptosis in atherogenesis promotes relatively thicker fibrous caps in smaller plaques, demonstrating the beneficial action of VSMC survival during atherogenesis or in advanced plaques. We demonstrate the important role of Akt in suppressing VSMC apoptosis and identify Apaf1 as a novel downstream apoptosis mediator regulated by FoxO3a. The current study indicates that suppression of chronic VSMC death might promote plaque stability and suggests some therapeutic targets in the pathway activated by Akt.
